ERNESTINA MELICOFF-PORTILLO
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Transplantation | 20 | 2023 | 310 | 5.380 |
Why?
|
| Cystic Fibrosis | 4 | 2022 | 257 | 1.530 |
Why?
|
| Lung Diseases | 2 | 2023 | 383 | 1.180 |
Why?
|
| Graft Rejection | 7 | 2021 | 588 | 1.020 |
Why?
|
| Waiting Lists | 3 | 2022 | 227 | 0.990 |
Why?
|
| Tissue and Organ Procurement | 2 | 2022 | 216 | 0.780 |
Why?
|
| Tissue Donors | 2 | 2022 | 486 | 0.760 |
Why?
|
| Vascular Diseases | 1 | 2023 | 166 | 0.730 |
Why?
|
| Familial Primary Pulmonary Hypertension | 1 | 2020 | 19 | 0.720 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2022 | 221 | 0.660 |
Why?
|
| Education, Medical, Continuing | 1 | 2019 | 138 | 0.600 |
Why?
|
| Postoperative Complications | 4 | 2018 | 3068 | 0.600 |
Why?
|
| Bacterial Infections | 1 | 2021 | 306 | 0.600 |
Why?
|
| Bronchiolitis Obliterans | 3 | 2022 | 40 | 0.540 |
Why?
|
| Bronchial Arteries | 1 | 2015 | 5 | 0.510 |
Why?
|
| Anti-Infective Agents | 1 | 2018 | 265 | 0.500 |
Why?
|
| Child | 24 | 2023 | 24526 | 0.500 |
Why?
|
| Synaptotagmin II | 4 | 2009 | 6 | 0.500 |
Why?
|
| Organ Transplantation | 3 | 2022 | 164 | 0.480 |
Why?
|
| Exocytosis | 4 | 2009 | 63 | 0.430 |
Why?
|
| Lung | 6 | 2022 | 1483 | 0.400 |
Why?
|
| Adolescent | 15 | 2023 | 19358 | 0.400 |
Why?
|
| Mast Cells | 2 | 2009 | 74 | 0.380 |
Why?
|
| Vascular Surgical Procedures | 1 | 2015 | 578 | 0.340 |
Why?
|
| Pediatrics | 1 | 2019 | 1163 | 0.340 |
Why?
|
| Incidence | 5 | 2021 | 3086 | 0.320 |
Why?
|
| Infant | 9 | 2023 | 12479 | 0.310 |
Why?
|
| Child, Preschool | 10 | 2023 | 14085 | 0.300 |
Why?
|
| Community-Acquired Infections | 2 | 2020 | 240 | 0.290 |
Why?
|
| Transplant Recipients | 4 | 2022 | 214 | 0.290 |
Why?
|
| Respiratory Tract Infections | 2 | 2020 | 270 | 0.270 |
Why?
|
| Retrospective Studies | 7 | 2023 | 16231 | 0.270 |
Why?
|
| Humans | 30 | 2023 | 124401 | 0.250 |
Why?
|
| Viral Load | 2 | 2017 | 384 | 0.250 |
Why?
|
| Survival Rate | 2 | 2023 | 2020 | 0.230 |
Why?
|
| Heart Transplantation | 2 | 2022 | 857 | 0.230 |
Why?
|
| Hypoxia | 2 | 2016 | 246 | 0.220 |
Why?
|
| Risk Factors | 8 | 2022 | 10149 | 0.220 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 2 | 2014 | 112 | 0.210 |
Why?
|
| Atrial Flutter | 1 | 2022 | 32 | 0.200 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2021 | 2088 | 0.200 |
Why?
|
| Heart-Lung Transplantation | 1 | 2022 | 23 | 0.200 |
Why?
|
| Calcium | 5 | 2009 | 1095 | 0.190 |
Why?
|
| Cryptococcosis | 1 | 2021 | 42 | 0.190 |
Why?
|
| Ribs | 1 | 2021 | 45 | 0.190 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2022 | 108 | 0.190 |
Why?
|
| Symptom Assessment | 1 | 2020 | 100 | 0.170 |
Why?
|
| Picornaviridae Infections | 1 | 2020 | 48 | 0.170 |
Why?
|
| Ventricular Function | 1 | 2020 | 92 | 0.170 |
Why?
|
| Immunosuppressive Agents | 2 | 2021 | 645 | 0.170 |
Why?
|
| Graft Survival | 2 | 2019 | 528 | 0.170 |
Why?
|
| Immunocompromised Host | 2 | 2020 | 295 | 0.170 |
Why?
|
| Postoperative Period | 1 | 2020 | 333 | 0.160 |
Why?
|
| Exercise Test | 1 | 2020 | 248 | 0.160 |
Why?
|
| Follow-Up Studies | 6 | 2020 | 5107 | 0.160 |
Why?
|
| Idiopathic Interstitial Pneumonias | 1 | 2019 | 8 | 0.160 |
Why?
|
| Hypertension, Pulmonary | 2 | 2016 | 433 | 0.160 |
Why?
|
| Pulmonary Fibrosis | 3 | 2016 | 105 | 0.160 |
Why?
|
| Osteomyelitis | 1 | 2021 | 205 | 0.160 |
Why?
|
| Certification | 1 | 2019 | 67 | 0.160 |
Why?
|
| Drug Resistance, Multiple | 1 | 2018 | 49 | 0.150 |
Why?
|
| Time Factors | 4 | 2018 | 6273 | 0.150 |
Why?
|
| Cold Ischemia | 1 | 2018 | 20 | 0.150 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2021 | 203 | 0.150 |
Why?
|
| Perioperative Care | 1 | 2020 | 197 | 0.150 |
Why?
|
| Synaptic Transmission | 3 | 2009 | 351 | 0.150 |
Why?
|
| Anelloviridae | 1 | 2017 | 1 | 0.150 |
Why?
|
| Operative Time | 1 | 2018 | 166 | 0.140 |
Why?
|
| Lung Diseases, Fungal | 1 | 2017 | 32 | 0.140 |
Why?
|
| Hodgkin Disease | 1 | 2020 | 293 | 0.140 |
Why?
|
| Male | 17 | 2021 | 61027 | 0.140 |
Why?
|
| Calcium Signaling | 2 | 2009 | 242 | 0.140 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2021 | 341 | 0.140 |
Why?
|
| Interleukin-6 | 3 | 2014 | 415 | 0.140 |
Why?
|
| United States | 3 | 2022 | 10773 | 0.140 |
Why?
|
| Pamphlets | 1 | 2016 | 23 | 0.130 |
Why?
|
| Virus Diseases | 1 | 2019 | 279 | 0.130 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2018 | 349 | 0.130 |
Why?
|
| Heart Ventricles | 1 | 2020 | 770 | 0.130 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2017 | 224 | 0.130 |
Why?
|
| Female | 15 | 2020 | 66303 | 0.130 |
Why?
|
| Atrial Fibrillation | 1 | 2022 | 637 | 0.120 |
Why?
|
| Echocardiography | 1 | 2020 | 1052 | 0.120 |
Why?
|
| Adenosine | 1 | 2016 | 127 | 0.120 |
Why?
|
| Deoxycytidine Kinase | 1 | 2014 | 2 | 0.120 |
Why?
|
| Bronchoscopy | 1 | 2015 | 153 | 0.120 |
Why?
|
| Macrophages, Alveolar | 1 | 2014 | 48 | 0.120 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2014 | 40 | 0.120 |
Why?
|
| Herpesvirus 4, Human | 1 | 2017 | 671 | 0.110 |
Why?
|
| Curriculum | 1 | 2019 | 725 | 0.110 |
Why?
|
| Patient Education as Topic | 1 | 2016 | 443 | 0.100 |
Why?
|
| Liver Transplantation | 1 | 2021 | 1039 | 0.100 |
Why?
|
| Receptor, Adenosine A2B | 1 | 2012 | 11 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 6 | 2014 | 4425 | 0.100 |
Why?
|
| Prospective Studies | 5 | 2022 | 6089 | 0.100 |
Why?
|
| Quality of Life | 1 | 2020 | 1954 | 0.090 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2012 | 147 | 0.090 |
Why?
|
| Mice | 10 | 2014 | 17729 | 0.080 |
Why?
|
| Mice, Knockout | 4 | 2014 | 3753 | 0.080 |
Why?
|
| Adult | 4 | 2022 | 29397 | 0.080 |
Why?
|
| Cells, Cultured | 3 | 2012 | 3052 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2020 | 3578 | 0.080 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2009 | 121 | 0.080 |
Why?
|
| Presynaptic Terminals | 1 | 2009 | 76 | 0.080 |
Why?
|
| Synaptic Vesicles | 1 | 2009 | 64 | 0.080 |
Why?
|
| Endocytosis | 1 | 2009 | 124 | 0.080 |
Why?
|
| Cytoplasmic Granules | 1 | 2009 | 47 | 0.080 |
Why?
|
| Cell Count | 1 | 2009 | 252 | 0.080 |
Why?
|
| Immunoblotting | 1 | 2009 | 313 | 0.080 |
Why?
|
| Calmodulin | 1 | 2009 | 230 | 0.080 |
Why?
|
| Cell Extracts | 1 | 2008 | 11 | 0.080 |
Why?
|
| Treatment Outcome | 2 | 2020 | 12286 | 0.070 |
Why?
|
| Goblet Cells | 1 | 2009 | 104 | 0.070 |
Why?
|
| Young Adult | 3 | 2017 | 8979 | 0.070 |
Why?
|
| Endoplasmic Reticulum | 1 | 2009 | 219 | 0.070 |
Why?
|
| Bone Marrow Cells | 1 | 2009 | 261 | 0.070 |
Why?
|
| Pneumonia, Pneumococcal | 1 | 2008 | 82 | 0.070 |
Why?
|
| Tryptases | 1 | 2007 | 20 | 0.070 |
Why?
|
| Hypersensitivity | 1 | 2009 | 183 | 0.070 |
Why?
|
| Texas | 1 | 2015 | 3590 | 0.070 |
Why?
|
| Neuromuscular Junction | 1 | 2006 | 92 | 0.070 |
Why?
|
| Neurotransmitter Agents | 1 | 2006 | 144 | 0.060 |
Why?
|
| Adjuvants, Immunologic | 1 | 2008 | 380 | 0.060 |
Why?
|
| Animals | 10 | 2014 | 34146 | 0.060 |
Why?
|
| Immunohistochemistry | 1 | 2009 | 1684 | 0.060 |
Why?
|
| Immunity, Innate | 1 | 2008 | 372 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2017 | 1017 | 0.060 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 1332 | 0.060 |
Why?
|
| Bronchoalveolar Lavage Fluid | 2 | 2017 | 151 | 0.050 |
Why?
|
| Synapses | 1 | 2006 | 460 | 0.050 |
Why?
|
| Organ Dysfunction Scores | 1 | 2022 | 48 | 0.050 |
Why?
|
| Tachycardia | 1 | 2022 | 70 | 0.050 |
Why?
|
| Interleukin-23 | 1 | 2022 | 12 | 0.050 |
Why?
|
| Signal Transduction | 1 | 2014 | 4535 | 0.050 |
Why?
|
| Cell Differentiation | 1 | 2009 | 1930 | 0.050 |
Why?
|
| Multiple Organ Failure | 1 | 2022 | 141 | 0.050 |
Why?
|
| Respiratory Mucosa | 2 | 2014 | 91 | 0.050 |
Why?
|
| Palivizumab | 1 | 2021 | 46 | 0.050 |
Why?
|
| Rituximab | 1 | 2021 | 156 | 0.040 |
Why?
|
| Tacrolimus | 1 | 2021 | 99 | 0.040 |
Why?
|
| Rhinovirus | 1 | 2020 | 59 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2009 | 2535 | 0.040 |
Why?
|
| Prognosis | 2 | 2019 | 4553 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2021 | 289 | 0.040 |
Why?
|
| Consensus | 1 | 2022 | 629 | 0.040 |
Why?
|
| Respiratory Function Tests | 1 | 2019 | 197 | 0.040 |
Why?
|
| Rats, Wistar | 2 | 2009 | 360 | 0.040 |
Why?
|
| Patient Selection | 1 | 2022 | 688 | 0.040 |
Why?
|
| Viruses | 1 | 2019 | 123 | 0.040 |
Why?
|
| Organoids | 1 | 2021 | 286 | 0.040 |
Why?
|
| Survivors | 1 | 2020 | 344 | 0.040 |
Why?
|
| Heart | 1 | 2022 | 718 | 0.030 |
Why?
|
| Immune Tolerance | 1 | 2017 | 145 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 1 | 2019 | 578 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2020 | 8184 | 0.030 |
Why?
|
| Cytokines | 1 | 2022 | 1279 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2021 | 1892 | 0.030 |
Why?
|
| Vascular Remodeling | 1 | 2016 | 41 | 0.030 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2016 | 98 | 0.030 |
Why?
|
| DNA, Viral | 1 | 2017 | 479 | 0.030 |
Why?
|
| Brain | 1 | 2006 | 3003 | 0.030 |
Why?
|
| Inflammation | 1 | 2022 | 1414 | 0.030 |
Why?
|
| Reoperation | 1 | 2017 | 831 | 0.030 |
Why?
|
| Fibronectins | 1 | 2014 | 104 | 0.030 |
Why?
|
| Myofibroblasts | 1 | 2014 | 75 | 0.030 |
Why?
|
| Pulmonary Alveoli | 1 | 2014 | 134 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2017 | 1584 | 0.030 |
Why?
|
| Collagen | 1 | 2014 | 313 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 510 | 0.030 |
Why?
|
| Rats | 2 | 2009 | 3687 | 0.030 |
Why?
|
| Adenosine-5'-(N-ethylcarboxamide) | 1 | 2012 | 1 | 0.020 |
Why?
|
| Purinergic P1 Receptor Agonists | 1 | 2012 | 5 | 0.020 |
Why?
|
| Mice, Transgenic | 2 | 2009 | 2408 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 2896 | 0.020 |
Why?
|
| Hospitalization | 1 | 2020 | 1756 | 0.020 |
Why?
|
| Endothelin-1 | 1 | 2012 | 39 | 0.020 |
Why?
|
| Purines | 1 | 2012 | 110 | 0.020 |
Why?
|
| Bleomycin | 1 | 2012 | 150 | 0.020 |
Why?
|
| Cell Line | 1 | 2014 | 2771 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2012 | 305 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2012 | 515 | 0.020 |
Why?
|
| Inositol 1,4,5-Trisphosphate Receptors | 1 | 2009 | 34 | 0.020 |
Why?
|
| Mucins | 1 | 2009 | 74 | 0.020 |
Why?
|
| Excitatory Postsynaptic Potentials | 1 | 2009 | 131 | 0.020 |
Why?
|
| Biomarkers | 1 | 2017 | 2980 | 0.020 |
Why?
|
| Colony Count, Microbial | 1 | 2008 | 89 | 0.020 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2008 | 105 | 0.020 |
Why?
|
| Aerosols | 1 | 2008 | 65 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2009 | 291 | 0.020 |
Why?
|
| Neutrophil Infiltration | 1 | 2008 | 64 | 0.020 |
Why?
|
| Central Nervous System | 1 | 2009 | 254 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2014 | 2304 | 0.020 |
Why?
|
| Klebsiella Infections | 1 | 2007 | 52 | 0.020 |
Why?
|
| Klebsiella pneumoniae | 1 | 2007 | 73 | 0.020 |
Why?
|
| Action Potentials | 1 | 2009 | 500 | 0.020 |
Why?
|
| Peptide Hydrolases | 1 | 2007 | 141 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2007 | 328 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2008 | 1006 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2006 | 412 | 0.020 |
Why?
|
| Cell Survival | 1 | 2006 | 806 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2008 | 1482 | 0.010 |
Why?
|
| Neoplasms | 1 | 2019 | 2800 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2007 | 672 | 0.010 |
Why?
|
| Bacteria | 1 | 2008 | 485 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2014 | 4355 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 2006 | 1008 | 0.010 |
Why?
|
| Neurons | 1 | 2009 | 1966 | 0.010 |
Why?
|
| Aged | 1 | 2016 | 19478 | 0.010 |
Why?
|